Takeda Pharmaceutical
298 hedge funds and large institutions have $1.02B invested in Takeda Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 118 increasing their positions, 84 reducing their positions, and 28 closing their positions.
1,086% more call options, than puts
Call options by funds: $28.2M | Put options by funds: $2.37M
61% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 28
40% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 84
5% more funds holding
Funds holding: 283 → 298 (+15)
0.23% more ownership
Funds ownership: 4.56% → 4.79% (+0.23%)
11% less capital invested
Capital invested by funds: $1.15B → $1.02B (-$129M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$45.1M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$32.9M |
| 3 |
Goldman Sachs
New York
|
+$12M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$8.46M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Groupama Asset Management
Paris,
France
|
-$204M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$37.5M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$14.8M |
| 4 |
Millennium Management
New York
|
-$13.3M |
| 5 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$8.31M |
TAK Hedge Fund Activity: Q3 2024 in Review
298 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2024, worth a combined $1.02B — down 11% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new TAK positions and 28 closed out — a net gain of 17 holders — while 118 added to existing stakes and 84 trimmed.
The largest buyer was First Trust Advisors, opening a new position worth an estimated $45.1M. The largest seller was Groupama Asset Management, exiting entirely with an estimated $204M sold.
- 298 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2024, up from 283 in Q2 2024.
- Funds reported $1.02B of Takeda Pharmaceutical stock for Q3 2024, down 11% quarter-over-quarter.
- 45 funds opened new Takeda Pharmaceutical positions in Q3 2024 and 28 closed out, a net change of +17 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2024 was First Trust Advisors, an estimated $45.1M added.
- The largest Takeda Pharmaceutical seller in Q3 2024 was Groupama Asset Management, an estimated $204M sold.
Based on aggregated 13F filings for Q3 2024.